3:41 PM
 | 
Jun 04, 2019
 |  BC Extra  |  Company News

Management tracks: Vericel, Theravance, Eisai

Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO on May 28 to become CEO of a private biotech company. SVP, Quality and Regulatory Affairs Michael Halpin will succeed Orlando as COO, effective June 15.

Inflammation and immunology company Theravance Biopharma Inc. (NASDAQ:TBPH) hired Andrew Hindman...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >